Ameritas Investment Partners’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-2,650
| Closed | -$100K | – | 3363 |
|
|
2021
Q1 | $100K | Buy |
2,650
+340
| +15% | +$8.48K | ﹤0.01% | 1676 |
|
|
2020
Q4 | $39K | Sell |
2,310
-480
| -17% | -$6.01K | ﹤0.01% | 2136 |
|
|
2020
Q3 | $13K | Hold |
2,790
| – | – | ﹤0.01% | 2619 |
|
|
2020
Q2 | $17K | Hold |
2,790
| – | – | ﹤0.01% | 2451 |
|
|
2020
Q1 | $6K | Hold |
2,790
| – | – | ﹤0.01% | 2791 |
|
|
2019
Q4 | $13K | Hold |
2,790
| – | – | ﹤0.01% | 2649 |
|
|
2019
Q3 | $11K | Hold |
2,790
| – | – | ﹤0.01% | 2729 |
|
|
2019
Q2 | $17K | Hold |
2,790
| – | – | ﹤0.01% | 2553 |
|
|
2019
Q1 | $37K | Hold |
2,790
| – | – | ﹤0.01% | 2058 |
|
|
2018
Q4 | $26K | Hold |
2,790
| – | – | ﹤0.01% | 2195 |
|
|
2018
Q3 | $39K | Hold |
2,790
| – | – | ﹤0.01% | 2130 |
|
|
2018
Q2 | $44K | Buy |
2,790
+460
| +20% | +$8.03K | ﹤0.01% | 2080 |
|
|
2018
Q1 | $40K | Hold |
2,330
| – | – | ﹤0.01% | 2045 |
|
|
2017
Q4 | $51K | Hold |
2,330
| – | – | ﹤0.01% | 1923 |
|
|
2017
Q3 | $79K | Hold |
2,330
| – | – | ﹤0.01% | 1606 |
|
|
2017
Q2 | $70K | Hold |
2,330
| – | – | ﹤0.01% | 1689 |
|
|
2017
Q1 | $84K | Buy |
+2,330
| New | +$103K | ﹤0.01% | 1527 |
|
Ameritas Investment Partners's FPRX Position: Q2 2021 in Review
Ameritas Investment Partners sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 2,650 shares — an estimated $100K sold.
Ameritas Investment Partners first reported a position in FPRX in Q1 2017 and held it in 17 quarters. The position peaked at $100K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Ameritas Investment Partners reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Ameritas Investment Partners sold 2,650 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $100K.
- Ameritas Investment Partners first reported a position in Five Prime Therapeutics, Inc. in Q1 2017 and held it in 17 quarters.
- Ameritas Investment Partners's Five Prime Therapeutics, Inc. position peaked at $100K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.